Literature DB >> 6306436

Presynaptic antagonist-postsynaptic agonist at muscarinic cholinergic synapses. N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.

O Nordström, P Alberts, A Westlind, A Undén, T Bartfai.   

Abstract

A muscarinic cholinergic ligand, N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)-acetamide (Compound BM-5), was shown to act simultaneously as a presynaptic antagonist and as a postsynaptic agonist at peripheral and central muscarinic synapses. In the presence of eserine it enhanced release of [3H]acetylcholine evoked by electrical stimulation in the guinea pig ileum longitudinal muscle myenteric plexus preparation. It also enhanced the release of [3H]acetylcholine evoked by potassium (25 mM) from rat hippocampal slices. It contracted the ileum and stimulated the synthesis of cyclic guanosine 3',5'-monophosphate in rat hippocampal slices and in human lymphocytes in a manner similar to the muscarinic agonist oxotremorine. This effect of BM-5 could be blocked by atropine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306436

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

1.  Behavioral and pharmacological unravelling of memory formation.

Authors:  M E Gibbs
Journal:  Neurochem Res       Date:  1991-06       Impact factor: 3.996

2.  The determination of presynaptic KA values of methacholine and pilocarpine and of a presynaptic receptor reserve in the rat perfused heart.

Authors:  P Fuchs; H Fuder
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

3.  BM-5, a centrally active partial muscarinic agonist with low tremorogenic activity. In vivo and in vitro studies.

Authors:  C Engström; A Undén; H Ladinsky; S Consolo; T Bartfai
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors.

Authors:  R J Hargreaves; A T McKnight; K Scholey; N R Newberry; L J Street; P H Hutson; J E Semark; E A Harley; S Patel; S B Freedman
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.